Dexamethasone palmitate 地塞米松棕榈酸酯; DXP|cas:14899-36-6|西域试剂

Dexamethasone palmitate 地塞米松棕榈酸酯; DXP,98.0%

产品编号：Bellancom-128922| CAS NO：14899-36-6| 分子式：C₃₈H₅₉FO₆| 分子量：630.87

Dexamethasone palmitate (DXP) 是 Dexamethasone 的前药。Dexamethasone 是一种糖皮质激素受体 (glucocorticoid receptor) 激动剂。Dexamethasone palmitate (DXP) 对糖皮质激素受体的亲和力比 Dexamethasone 低 47 倍。具有抗炎活性。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-128922	￥950.00	杭州北京（现货）
Bellancom-128922	￥1600.00	杭州北京（现货）
Bellancom-128922	￥3400.00	杭州北京（现货）
Bellancom-128922	￥5800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Dexamethasone palmitate 地塞米松棕榈酸酯; DXP

产品介绍

Dexamethasone palmitate (DXP) 是 Dexamethasone (HY-14648) 的前体活性分子。Dexamethasone palmitate 可用于炎症的研究。

生物活性

Dexamethasone palmitate (DXP) is a proagent of Dexamethasone (HY-14648). Dexamethasone palmitate can be used for the research of inflammation.

体外研究

Dexamethasone palmitate (100 μg/mL; 48 h) affects cytokines concentration of RAW 264.7 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	RAW 264.7 cells
Concentration:	100 μg/mL
Incubation Time:	48 hours
Result:	Showed vitro anti-inflammatory effects and decreased LPS-induced MCP-1 and TNF-α concentration in RAW 264.7 cells.

体内研究
(In Vivo)

Dexamethasone palmitate (1280 μg; IVT injection once) shows different distribution in ocular tissue at different times.
Dexamethasone palmitate (280-1280 μg; IVT injection once) affects VEGF-induced vascular hyperpermeability.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	New Zealand White rabbits
Dosage:	1280 μg
Administration:	IVT injection; 1280 μg once
Result:	Mostly distributed in vitreous and still existed till 9 months. The least distributed in aqueous humor and almost disappeared till 6 months.

Animal Model:	New Zealand White rabbits with VEGF injection
Dosage:	280, 560 and 1280 μg
Administration:	IVT injection; 280-1280 μg once
Result:	After 9 months administration VEGF-induced vascular permeability was controlled at a concentration of 1280 μg, besides 280 and 560 μg also reduced VEGF-induced vascular hyperpermeability after administration for 4 months.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	New Zealand White rabbits
Dosage:	1280 μg
Administration:	IVT injection; 1280 μg once
Result:	Mostly distributed in vitreous and still existed till 9 months. The least distributed in aqueous humor and almost disappeared till 6 months.

Animal Model:	New Zealand White rabbits with VEGF injection
Dosage:	280, 560 and 1280 μg
Administration:	IVT injection; 280-1280 μg once
Result:	After 9 months administration VEGF-induced vascular permeability was controlled at a concentration of 1280 μg, besides 280 and 560 μg also reduced VEGF-induced vascular hyperpermeability after administration for 4 months.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	New Zealand White rabbits
Dosage:	1280 μg
Administration:	IVT injection; 1280 μg once
Result:	Mostly distributed in vitreous and still existed till 9 months. The least distributed in aqueous humor and almost disappeared till 6 months.

Animal Model:	New Zealand White rabbits with VEGF injection
Dosage:	280, 560 and 1280 μg
Administration:	IVT injection; 280-1280 μg once
Result:	After 9 months administration VEGF-induced vascular permeability was controlled at a concentration of 1280 μg, besides 280 and 560 μg also reduced VEGF-induced vascular hyperpermeability after administration for 4 months.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (79.26 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5851 mL	7.9256 mL	15.8511 mL
5 mM	0.3170 mL	1.5851 mL	3.1702 mL
10 mM	0.1585 mL	0.7926 mL	1.5851 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.30 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (3.30 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (3.30 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Lorscheider M, et al. Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. J Control Release. 2019 Feb 28;296:179-189. [Content Brief]

. Daull P, et al. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013 Mar;29(2):258-69. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

Dexamethasone palmitate 地塞米松棕榈酸酯; DXP,98.0%

Dexamethasone palmitate 地塞米松棕榈酸酯; DXP

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询